In addition to ibrutinib, clients with M-CLL, devoid of TP53 aberrations and healthy ample to tolerate FCR therapy, may still be great candidates to the latter, While using the advantage remaining that this treatment method can be accomplished in 6 months whilst ibrutinib has to be taken indefinitely. This option could be specifically important for